

**REVENUE**

₹ 1048 Crores

↑ 22%

EBITDA

₹ 241 Crores

↑ 58%

PAT

₹ 79 Crores

↑ 8%

Jubilant Life Sciences Limited (Formerly Jubilant Organosys Limited)
Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)

Unaudited Financial Results for the Quarter and Half year ended 30th September, 2011

[₹ in Lacs]

[₹ in Lacs]

STAND ALONE RESULTS					Particulars	CONSOLIDATED RESULTS					Statement of Assets And Liabilities						
Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)	STAND ALONE		Particulars	CONSOLIDATED			
2011	2010	2011	2010	2011		2011	2010	2011	2010	2011	As at September 30 (Unaudited)	As at March 31 (Audited)		As at September 30 (Unaudited)	As at March 31 (Audited)		
62837	54062	124539	106093	220089	Net sales/Income from operations	104808	85897	199237	167659	343340	1593	1588	1593	Share holders Funds	1593	1588	1593
266	40	439	73	541	Other Operating Income	200	131	619	230	883	212551	204344	212466	a) Capital	236348	203941	215634
63103	54102	124978	106166	220630	Total income	105008	86028	199856	167889	344223	-	-	-	b) Reserves and Surplus	6068	3923	4181
54963	44023	107170	86435	186069	Total Expenditure	86282	76131	167486	148684	306812	266216	181296	298933	Minority Interest	361736	287081	388416
(2467)	(116)	(4684)	(1951)	(3131)	a) (Increase)/Decrease in stock in trade and work in progress	(4522)	876	(8723)	(1905)	(3880)	-	-	-	Loan from Banks, Institutions and FCCB's	-	4621	4036
6065	5446	11569	10275	21637	b) Purchase of traded goods	6554	4551	13139	10314	24007	19907	21877	18990	Loan from Customers	23087	23631	21070
29893	21054	58348	43391	90143	c) Raw & process materials consumed	36657	27362	70235	55563	112943	500267	409105	531982	Deferred Tax Liabilities (Net)	628832	524785	634930
2232	2023	5092	4250	9424	d) Stores, spares, chemicals, catalyst & packing material consumed	5113	5068	10985	10433	21188	212770	179191	196391	TOTAL	499566	437630	466881
5349	4882	10893	9604	20665	e) Power & fuel	5822	5368	11823	10521	22404	8035	-	-	Fixed Assets	8035	2484	-
1801	1393	3064	2407	4895	f) Other manufacturing expenses	2539	1851	4342	3289	6965	190237	177119	186405	Investments-In Liquid Funds	3634	3278	3275
5090	4128	9768	7927	17317	g) Staff cost	20603	18081	39579	35778	71842	-	-	-	Investments-Others	6695	4421	3950
2921	2475	5689	4868	9991	h) Depreciation	5080	4926	10057	9768	18010	5274	17	-	Deferred Tax Assets (Net)	5274	1141	-
4079	2738	7431	5664	15128	i) Other Expenditure (Selling, general & admin. Expenses-Including Exchange Loss/Gain)	8436	8048	16049	14923	33333	49847	34071	40470	Foreign Currency Monetary Items Translation Difference Account (FCMITDA)	-	-	-
8140	10079	17808	19731	34561	Operating Profit before Other Income & Interest	18726	9897	32370	19205	37411	30978	35275	33452	Current Assets, Loans and Advances	86013	61670	69128
229	49	464	116	514	Other Income	340	424	707	657	1296	895	4837	98526	a) Inventories	58225	53968	52045
8369	10128	18272	19847	35075	Profit before Interest & Exceptional Items	19066	10321	33077	19862	38707	77034	59298	71822	b) Sundry Debtors	10115	11621	104569
3599	854	6600	1406	4625	Interest (Net)	4969	2476	9307	4423	10506	59998	37383	54483	c) Cash and Bank balances	-	-	-
4770	9274	11672	18441	30450	Profit after Interest but before Exceptional Items	14097	7845	23770	15439	28201	14805	43320	40601	d) Other Current Assets	63878	52454	56537
4160	(624)	4428	577	455	Exceptional items	4260	291	4678	2371	4142	500267	409105	531982	e) Loans and Advances	91349	58955	78614
610	9898	7244	17864	29995	Profit from Ordinary Activities before Tax	9837	7554	19092	13068	24059	77034	59298	71822	Less : Current Liabilities and Provisions	21254	44927	42841
110	1024	1355	2211	2032	Tax Expenses (Net)	930	260	2446	838	1336	59998	37383	54483	a) Liabilities	-	-	-
500	8874	5889	15653	27963	Net Profit from Ordinary Activities after Tax	8907	7294	16646	12230	22723	14805	43320	40601	b) Provisions	-	-	-
-	-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-	-	-	-	-	Miscellaneous Expenditure (Not Written Off or Adjusted)	-	-	-
-	-	-	-	-	Minority Interest	971	(52)	998	(159)	(249)	500267	409105	531982	TOTAL	628832	524785	634930
500	8874	5889	15653	27963	Net Profit after Minority Interest	7936	7346	15648	12389	22972	500267	409105	531982	TOTAL	628832	524785	634930
1593	1588	1593	1588	1593	Paid-up Share Capital (Face value per share ₹ 1)	1593	1588	1593	1588	1593	500267	409105	531982	TOTAL	628832	524785	634930
				212466	Reserves (excluding revaluation reserve)					215634							
0.31	5.57	3.69	9.83	17.56	Earnings per share before and after extraordinary items (Not annualized)	4.98	4.61	9.82	7.78	14.42							
0.31	5.04	3.69	8.89	15.87	Basic (₹)	4.98	4.61	9.82	7.78	14.42							
					Diluted (₹)	4.98	4.17	9.82	7.03	13.04							
					Public Shareholding												
81344677	83627751	81344677	83627751	84129115	- Number of shares (₹ 1 each)	81344677	83627751	81344677	83627751	84129115							
51.07	52.67	51.07	52.67	52.82	- Percentage of shareholding	51.07	52.67	51.07	52.67	52.82							
					Promoters and promoter group Shareholding												
					a) Pledged/Encumbered												
6552333	8928300	6552333	8928300	7531333	- Number of shares	6552333	8928300	6552333	8928300	7531333							
8.41	11.88	8.41	11.88	10.02	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	8.41	11.88	8.41	11.88	10.02							
4.11	5.62	4.11	5.62	4.73	- Percentage of shares (as a % of the total share capital of the company)	4.11	5.62	4.11	5.62	4.73							
					b) Non-Encumbered												
71384129	66223724	71384129	66223724	67620691	- Number of shares	71384129	66223724	71384129	66223724	67620691							
91.59	88.12	91.59	88.12	89.98	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	91.59	88.12	91.59	88.12	89.98							
44.82	41.71	44.82	41.71	42.45	- Percentage of shares (as a % of the total share capital of the company)	44.82	41.71	44.82	41.71	42.45							

Notes:

- During the Quarter Cadista Holdings Inc. USA, our step down subsidiary where the company holds 82.38% equity, carrying on its generic business through a wholly owned subsidiary, Jubilant Cadista Pharmaceuticals Inc. USA, was registered with the Securities and Exchange Commission (SEC) of United States of America, under Section 12 (g) of the Securities and Exchange Control Act, United States of America.
- The Company operates under one reportable segment viz. Pharmaceuticals and Life Sciences Products and Services (PLSPS).
- During the Quarter the Company has opted for cash flow hedge accounting, in respect of certain transactions, under AS 30 issued by the Institute of Chartered Accountants of India. Accordingly, foreign exchange translation loss of ₹ 1483 Lacs has been debited to hedging reserve account.
- Exceptional items include :
 - Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 2637 Lacs (Consolidated ₹ 2637 Lacs) for Q2-FY 2012 and ₹ 2851 Lacs (Consolidated ₹ 2851 Lacs) for H1-FY 2012.
 - Mark to Market in respect of Currency and Interest rate swap contracts outstanding at the period end resulting in loss/(gain) amounting to ₹ 1523 Lacs (Consolidated ₹ 1623 Lacs) for Q2 FY 2012 and ₹ 1577 Lacs (Consolidated ₹ 1827 Lacs) for H1-FY 2012.
- Tax Expenses (Net) is after considering the MAT Credit Entitlement ₹ 1464 Lacs (Consolidated ₹ 1737 Lacs) for H1-FY 2012.
- The Compensation Committee of the Board on 24th October, 2011, has granted 862461 options to eligible Employees/ Directors of the Company and its subsidiaries as per JLL Employees Stock Option Plan 2011. Each option shall entitle the holder to acquire 1 equity share of ₹ 1 each fully paid at ₹ 200.05, being the market price as per SEBI guidelines. There is no dilution envisaged on account of this grant.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -23, Disposals -23, Closing Balance - Nil.
- The results for the corresponding quarter/six months has been recasted to give effect to the Scheme of Amalgamation & Demerger approved by Hon'ble High Court of Judicature, Allahabad during FY 2011 with effect from 1st April 2010.
- Previous year / periods figures have been regrouped/reclassified wherever necessary.
- The above un-audited results were, subjected to limited review by the auditors of the Company, reviewed by the Audit Committee at its meeting held on 31st October, 2011 and approved by the Board of Directors at its meeting held on 1st November, 2011.

For Jubilant Life Sciences Limited

Place : Noida

Date : 1st November, 2011 visit us at www.jubl.com

Shyam S Bhartia

Chairman & Managing Director